InMode Ltd. (NASDAQ:INMD) Is Favoured by Institutional Owners Who Hold 67% of the Company
To get a sense of who is truly in control of InMode Ltd. (NASDAQ:INMD), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 67% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
The Most Crowded Longs and Shorts in U.S. Med-Tech for May - UBS
Great Week for InMode Ltd. (NASDAQ:INMD) Institutional Investors After Losing 44% Over the Previous Year
Key Insights Significantly high institutional ownership implies InMode's stock price is sensitive to their trading actions 49% of the business is held by the top 25 shareholders Using data from an
InMode to Present at Jefferies Healthcare Conference
YOKNEAM, Israel, May 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer and Sp
InMode, Driver Ink Deal
InMode Announces P1 Offshore Racing Partnership With Female Driver Victoria Rand
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is the first aesthetic company to officially partner with...
InMode Ltd. (NASDAQ:INMD) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
InMode (NASDAQ:INMD) has had a rough three months with its share price down 25%. But if you pay close attention, you might gather that its strong financials could mean that the stock could potential
InMode Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating
InMode (INMD) has an average outperform rating and a price target range of $20 to $33, according to analysts polled by Capital IQ. Price: 17.52, Change: +0.16, Percent Change: +0.92
Needham: Reiterates that InMode (INMD.US) holds the rating.
Needham: Reiterates that InMode (INMD.US) holds the rating.
Needham Reiterates Hold on InMode
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.
InMode Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 — Needham Reiterates → Hold 04/12/2024 86.44% Barclays $34 → $33 Maintains Overweight 04/09/20
Earnings Call Summary | InMode(INMD.US) Q1 2024 Earnings Conference
The following is a summary of the InMode Ltd. (INMD) Q1 2024 Earnings Call Transcript:Financial Performance:InMode reported Q1 2024 revenue of $80.3 million. Pro forma revenue, including pre-orders no
Analysts Conflicted on These Healthcare Names: InMode (INMD) and Pfizer (PFE)
InMode Shares Rise; Q1 Non-GAAP Earnings, Revenue Fall; 2024 Guidance Cut
InMode (INMD) shares rose 2.4% in recent Thursday even after the company reported declines in Q1 profit and revenue and cut 2024 guidance. The medical-products company reported Q1 non-GAAP earnings of
InMode (INMD.US): The 2024 Q1 financial report achieved revenue of US$80.284 million, prior value of US$106.1 million, expected value of US$93.02 million; earnings per share were US$0.32, previous value was US$0.52, and expected value was US$0.44.
InMode (INMD.US): The 2024 Q1 financial report achieved revenue of US$80.284 million, prior value of US$106.1 million, expected value of US$93.02 million; earnings per share were US$0.32, previous value was US$0.52, and expected value was US$0.44.
InMode Announces Q1 Results and Share Buyback
InMode Cuts 2024 View To Rev $485M-$495M >INMD
InMode Cuts 2024 View To Rev $485M-$495M >INMD
InMode Appoints Michael Anghel Chairman of the Board Effective July 25 >INMD
InMode Appoints Michael Anghel Chairman of the Board Effective July 25 >INMD
InMode Announces Shr Repurchase Program of Up to 8.37M Shrs >INMD
InMode Announces Shr Repurchase Program of Up to 8.37M Shrs >INMD